Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation

The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation

(2020) Ganesan Karthikeyan et al.   AMERICAN HEART JOURNAL

A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial

(2020) Helio P. Guimarães et al.   AMERICAN HEART JOURNAL

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

(2019) Craig T. January et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Management of atrial fibrillation in patients with rheumatic mitral stenosis

(2018) Bernard Iung et al.   HEART

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

(2017) John W. Eikelboom et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta‐Analysis

(2017) Kuo‐Li Pan et al.   Journal of the American Heart Association

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

(2013) Christian T Ruff et al.   LANCET

Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm

(2012) Shunichi Homma et al.   NEW ENGLAND JOURNAL OF MEDICINE